MedTrace Logo

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

NCT00281554 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 254

Last updated 2008-04-03

No results posted yet for this study

Summary

This study is designed to determine the safety of RSD1235 in patients with atrial fibrillation.

Conditions

Interventions

DRUG

RSD1235

IV

Sponsors & Collaborators

  • Advanz Pharma

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma US, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States
  • Argentina
  • Canada
  • Denmark
  • South Africa
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00281554 on ClinicalTrials.gov